FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Gibb

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Co-author Network

Publications

TOP 3
Gregory C Hadlock; Glen R Hanson; Amanda J Hoonakker; Lisa M McFadden; Paula L Vieira-Brock; Katy M Webb; Diana G Wilkins; Scott C Allen; David M Andrenyak; Pei Wen Chu; Kevin M Conrad; Jonathan D Ellis; Christopher L German; James W Gibb; Annette E Fleckenstein
4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.
Lisa M McFadden; Amanda J Hoonakker; Paula L Vieira-Brock; Kristen A Stout; Nicole M Sawada; Jonathan D Ellis; Scott C Allen; Elliot T Walters; Shannon M Nielsen; James W Gibb; Mario E Alburges; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.
Jarom E Hanson; Elisabeth Birdsall; Kristi S Seferian; Marcus A Crosby; Kristen A Keefe; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Gibb (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Gregory C Hadlock; Glen R Hanson; Amanda J Hoonakker; Lisa M McFadden; Paula L Vieira-Brock; Katy M Webb; Diana G Wilkins; Scott C Allen; David M Andrenyak; Pei Wen Chu; Kevin M Conrad; Jonathan D Ellis; Christopher L German; James W Gibb; Annette E Fleckenstein
4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.
The Journal of pharmacology and experimental therapeutics 2011;339(2):530-6.
2011: Lisa M McFadden; Amanda J Hoonakker; Paula L Vieira-Brock; Kristen A Stout; Nicole M Sawada; Jonathan D Ellis; Scott C Allen; Elliot T Walters; Shannon M Nielsen; James W Gibb; Mario E Alburges; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.
Synapse (New York, N.Y.) 2011;65(8):771-7.
2009: Jarom E Hanson; Elisabeth Birdsall; Kristi S Seferian; Marcus A Crosby; Kristen A Keefe; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.
European journal of pharmacology 2009;607(1-3):68-73.
2009: Gregory C Hadlock; Anthony J Baucum; Jill L King; Kristen Ashley Horner; Glen A Cook; James W Gibb; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.
The Journal of pharmacology and experimental therapeutics 2009;329(1):169-74.
2007: Annette E Fleckenstein; Trent J Volz; Evan Riddle; James W Gibb; Glen R Hanson
New insights into the mechanism of action of amphetamines.
Annual review of pharmacology and toxicology 2007;47():681-98.
2006: Kristi S Rau; Elisabeth Birdsall; Trent J Volz; James A Riordan; Anthony J Baucum; Brian P Adair; Rebecca Bitter; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake.
The Journal of pharmacology and experimental therapeutics 2006;318(2):676-82.
2005: Kristi S Rau; Elisabeth Birdsall; Jarom E Hanson; Kamisha L Johnson-Davis; Frank carroll; Diana G Wilkins; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Bupropion increases striatal vesicular monoamine transport.
Neuropharmacology 2005;49(6):820-30.
2005: Jannine G Truong; Diana G Wilkins; Jakub Baudys; Dennis Crouch; Kamisha L Johnson-Davis; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.
The Journal of pharmacology and experimental therapeutics 2005;314(3):1087-92.
2002: Jeffrey M Brown; Evan Riddle; Verónica Sandoval; Raul K Weston; Jarom E Hanson; Michael J Crosby; Yvette V Ugarte; James W Gibb; Glen R Hanson; Annette E Fleckenstein
A single methamphetamine administration rapidly decreases vesicular dopamine uptake.
The Journal of pharmacology and experimental therapeutics 2002;302(2):497-501.
2002: J Paul Hansen; Evan Riddle; Verónica Sandoval; Jeffrey M Brown; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
The Journal of pharmacology and experimental therapeutics 2002;300(3):1093-100.
2000: Ryan R Metzger; HM Haughey; Diana G Wilkins; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia.
The Journal of pharmacology and experimental therapeutics 2000;295(3):1077-85.
2000: Annette E Fleckenstein; James W Gibb; Glen R Hanson
Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity.
European journal of pharmacology 2000;406(1):1-13.
1999: Annette E Fleckenstein; HM Haughey; Ryan R Metzger; Jerry M Kokoshka; Evan Riddle; Jarom E Hanson; James W Gibb; Glen R Hanson
Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function.
European journal of pharmacology 1999;382(1):45-9.
1998: Jerry M Kokoshka; Ryan R Metzger; Diana G Wilkins; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain.
Brain research 1998;799(1):78-83.
1998: Glen R Hanson; James W Gibb; Ryan R Metzger; Jerry M Kokoshka; Annette E Fleckenstein
Methamphetamine-induced rapid and reversible reduction in the activities of tryptophan hydroxylase and dopamine transporters: oxidative consequences?
Annals of the New York Academy of Sciences 1998;844():103-7.
1998: Ryan R Metzger; Glen R Hanson; James W Gibb; Annette E Fleckenstein
3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function.
European journal of pharmacology 1998;349(2-3):205-10.
1998: Glen R Hanson; J D Wagstaff; K Merchant; James W Gibb
Psychostimulants and neuropeptide response.
Advances in pharmacology (San Diego, Calif.) 1998;42():1014-6.
1997: M P Gygi; Annette E Fleckenstein; James W Gibb; Glen R Hanson
Role of endogenous dopamine in the neurochemical deficits induced by methcathinone.
The Journal of pharmacology and experimental therapeutics 1997;283(3):1350-5.
1997: James W Gibb; Lloyd Bush; Glen R Hanson
Exacerbation of methamphetamine-induced neurochemical deficits by melatonin.
The Journal of pharmacology and experimental therapeutics 1997;283(2):630-5.
1997: Annette E Fleckenstein; Diana G Wilkins; James W Gibb; Glen R Hanson
Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration.
The Journal of pharmacology and experimental therapeutics 1997;283(1):281-5.
1997: Annette E Fleckenstein; Ryan R Metzger; M L Beyeler; James W Gibb; Glen R Hanson
Oxygen radicals diminish dopamine transporter function in rat striatum.
European journal of pharmacology 1997;334(1):111-4.
1997: Annette E Fleckenstein; Ryan R Metzger; Diana G Wilkins; James W Gibb; Glen R Hanson
Rapid and reversible effects of methamphetamine on dopamine transporters.
The Journal of pharmacology and experimental therapeutics 1997;282(2):834-8.
1997: Annette E Fleckenstein; M L Beyeler; J C Jackson; Diana G Wilkins; James W Gibb; Glen R Hanson
Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters.
European journal of pharmacology 1997;324(2-3):179-86.
1997: Annette E Fleckenstein; Ryan R Metzger; James W Gibb; Glen R Hanson
A rapid and reversible change in dopamine transporters induced by methamphetamine.
European journal of pharmacology 1997;323(2-3):R9-10.
1997: J D Wagstaff; James W Gibb; Glen R Hanson
Role of dopamine D1- and NMDA receptors in regulating neurotensin release in the striatum and nucleus accumbens.
Brain research 1997;748(1-2):241-4.
1997: James W Gibb; M Johnson; I Elayan; H K Lim; L Matsuda; Glen R Hanson
Neurotoxicity of amphetamines and their metabolites.
NIDA research monograph 1997;173():128-45.
1997: Glen R Hanson; Lloyd Bush; VL Taylor; James W Gibb; K Davis; CJ Schmidt
Comparison of neurotensin responses to MDL 100,907, a selective 5HT2A antagonist, with clozapine and haloperidol.
Brain research bulletin 1997;42(3):211-9.
1996: J D Wagstaff; James W Gibb; Glen R Hanson
Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens.
The Journal of pharmacology and experimental therapeutics 1996;278(2):547-54.
1996: M P Gygi; S P Gygi; M Johnson; D G Wilkins; James W Gibb; Glen R Hanson
Mechanisms for tolerance to methamphetamine effects.
Neuropharmacology 1996;35(6):751-7.
1996: J D Wagstaff; James W Gibb; Glen R Hanson
Dopamine D2-receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis.
Brain research 1996;721(1-2):196-203.
1996: M P Gygi; James W Gibb; Glen R Hanson
Methcathinone: an initial study of its effects on monoaminergic systems.
The Journal of pharmacology and experimental therapeutics 1996;276(3):1066-72.
1995: S Che; M Johnson; Glen R Hanson; James W Gibb
Body temperature effect on methylenedioxymethamphetamine-induced acute decrease in tryptophan hydroxylase activity.
European journal of pharmacology 1995;293(4):447-53.
1995: Glen R Hanson; L P Midgley; L G Bush; James W Gibb
Response of extrapyramidal and limbic neurotensin systems to phencyclidine treatment.
European journal of pharmacology 1995;278(2):167-73.
1995: Glen R Hanson; N Singh; K Merchant; M Johnson; James W Gibb
The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse.
Drug and alcohol dependence 1995;37(2):107-10.
1994: J D Wagstaff; L G Bush; James W Gibb; Glen R Hanson
Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity.
Brain research 1994;665(2):237-44.
1994: M Johnson; Glen R Hanson; James W Gibb; John C Adair; Francis M Filloux
Effect of neonatal hypoxia-ischemia on nigro-striatal dopamine receptors and on striatal neuropeptide Y, dynorphin A and substance P concentrations in rats.
Brain research. Developmental brain research 1994;83(1):109-18.
1994: M Johnson; P K Sonsalla; A A Letter; Glen R Hanson; James W Gibb
Role of the 5-HT2 receptor in the methamphetamine-induced neurochemical alterations.
The Journal of pharmacology and experimental therapeutics 1994;270(1):97-103.
1994: S P Gygi; James W Gibb; Glen R Hanson
Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions.
The Journal of pharmacology and experimental therapeutics 1994;270(1):192-7.
1994: L P Midgley; J D Wagstaff; Nanda A Singh; L G Bush; James W Gibb; Glen R Hanson
Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbens regions.
European journal of pharmacology 1994;251(2-3):191-9.
1993: K W Elkins; James W Gibb; Glen R Hanson; D G Wilkins; M Johnson
Effects of nimodipine on the amphetamine- and methamphetamine-induced decrease in tryptophan hydroxylase activity.
European journal of pharmacology 1993;250(3):395-402.
1993: S P Gygi; James W Gibb; M Johnson; Glen R Hanson
Blockade of tachykinin NK1 receptors by CP-96345 enhances dopamine release and the striatal dopamine effects of methamphetamine in rats.
European journal of pharmacology 1993;250(1):177-80.
1993: L P Midgley; L G Bush; James W Gibb; Glen R Hanson
Differential regulation of neuropeptide Y systems in limbic structures of the rat.
The Journal of pharmacology and experimental therapeutics 1993;267(2):707-13.
1993: M Johnson; L G Bush; Glen R Hanson; James W Gibb
Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striatal neurotensin and dynorphin A concentrations.
Biochemical pharmacology 1993;46(4):770-2.
1993: I Elayan; James W Gibb; Glen R Hanson; H K Lim; Rodger L Foltz; M Johnson
Short-term effects of 2,4,5-trihydroxyamphetamine, 2,4,5-trihydroxymethamphetamine and 3,4-dihydroxymethamphetamine on central tryptophan hydroxylase activity.
The Journal of pharmacology and experimental therapeutics 1993;265(2):813-8.
1993: James W Gibb; M Johnson; D M Stone; Glen R Hanson
Mechanisms mediating biogenic amine deficits induced by amphetamine and its congeners.
NIDA research monograph 1993;136():226-36; discussion 236-41.
1992: I Elayan; James W Gibb; Glen R Hanson; Rodger L Foltz; H K Lim; M Johnson
Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine but not by 2-hydroxy-4,5-methylenedioxymethamphetamine or 2-hydroxy-4,5-methylenedioxyamphetamine.
European journal of pharmacology 1992;221(2-3):281-8.
1992: L P Midgley; L G Bush; James W Gibb; Glen R Hanson
Characterization of phencyclidine-induced effects on neuropeptide Y systems in the rat caudate-putamen.
Brain research 1992;593(1):89-96.
1992: Glen R Hanson; C F Bunker; M Johnson; L Bush; James W Gibb
Response of monoaminergic and neuropeptide systems to 4-methylaminorex: a new stimulant of abuse.
European journal of pharmacology 1992;218(2-3):287-93.
1992: M Johnson; K Mitros; D M Stone; R Zobrist; Glen R Hanson; James W Gibb
Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine.
The Journal of pharmacology and experimental therapeutics 1992;261(2):586-91.
1992: M Johnson; I Elayan; Glen R Hanson; Rodger L Foltz; James W Gibb; H K Lim
Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems.
The Journal of pharmacology and experimental therapeutics 1992;261(2):447-53.
1992: Nanda A Singh; L G Bush; James W Gibb; Glen R Hanson
Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems.
Brain research 1992;571(2):260-4.
1992: M Johnson; L G Bush; L Midgley; James W Gibb; Glen R Hanson
MK-801 blocks the changes in neurotensin concentrations induced by methamphetamine, 3,4-methylenedioxymethamphetamine, cocaine, and GBR 12909.
Annals of the New York Academy of Sciences 1992;668():350-2.
1992: Glen R Hanson; N Singh; K Merchant; M Johnson; L Bush; James W Gibb
Responses of limbic and extrapyramidal neurotensin systems to stimulants of abuse. Involvement of dopaminergic mechanisms.
Annals of the New York Academy of Sciences 1992;668():165-72.
1992: Mario E Alburges; Glen R Hanson; James W Gibb; C O Sakashita; Douglas E Rollins
Fentanyl receptor assay. II. Utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine.
Journal of analytical toxicology 1992;16(1):36-41.
1991: Glen R Hanson; N Singh; L Bush; James W Gibb
Response of extrapyramidal and limbic neuropeptides to fenfluramine administration: comparison with methamphetamine.
The Journal of pharmacology and experimental therapeutics 1991;259(3):1197-202.
1991: Mario E Alburges; Glen R Hanson; James W Gibb; C O Sakashita; Douglas E Rollins
Fentanyl receptor assay. I. Development of a radioreceptor assay for analysis of fentanyl and fentanyl analogs in urine.
Journal of analytical toxicology 1991;15(6):311-8.
1991: Nanda A Singh; L P Midgley; L G Bush; James W Gibb; Glen R Hanson
N-Methyl-D-aspartate receptors mediate dopamine-induced changes in extrapyramidal and limbic dynorphin systems.
Brain research 1991;555(2):233-8.
1991: M Johnson; Glen R Hanson; James W Gibb
Norepinephrine does not contribute to methamphetamine-induced changes in hippocampal serotonergic system.
Neuropharmacology 1991;30(6):617-22.
1991: M Johnson; L G Bush; James W Gibb; Glen R Hanson
Role of N-methyl-D-aspartate (NMDA) receptors in the response of extrapyramidal neurotensin and dynorphin A systems to cocaine and GBR 12909.
Biochemical pharmacology 1991;41(4):649-52.
1991: M Johnson; L G Bush; James W Gibb; Glen R Hanson
Blockade of the 3,4-methylenedioxymethamphetamine-induced changes in neurotensin and dynorphin A systems.
European journal of pharmacology 1991;193(3):367-70.
1990: K M Merchant; L G Bush; James W Gibb; Glen R Hanson
Neurotensin-dopamine interactions in the substantia nigra of the rat brain.
The Journal of pharmacology and experimental therapeutics 1990;255(2):775-80.
1990: Nanda A Singh; L G Bush; James W Gibb; Glen R Hanson
Dopamine-mediated changes in central nervous system neurotensin systems: a role for NMDA receptors.
European journal of pharmacology 1990;187(3):337-44.
1990: P L Smiley; M Johnson; L Bush; James W Gibb; Glen R Hanson
Effects of cocaine on extrapyramidal and limbic dynorphin systems.
The Journal of pharmacology and experimental therapeutics 1990;253(3):938-43.
1990: C F Bunker; M Johnson; James W Gibb; L G Bush; Glen R Hanson
Neurochemical effects of an acute treatment with 4-methylaminorex: a new stimulant of abuse.
European journal of pharmacology 1990;180(1):103-11.
1990: James W Gibb; M Johnson; D Stone; Glen R Hanson
MDMA: historical perspectives.
Annals of the New York Academy of Sciences 1990;600():601-11; discussion 611-2.
1990: James W Gibb; M Johnson; Glen R Hanson
Neurochemical basis of neurotoxicity.
Neurotoxicology 1990;11(2):317-21.
1990: Glen R Hanson; N Singh; L Bush; James W Gibb
Role of NMDA receptors in methamphetamine-induced changes in extrapyramidal and limbic neuropeptide systems.
NIDA research monograph 1990;105():439.
1989: L A Matsuda; Glen R Hanson; James W Gibb
Neurochemical effects of amphetamine metabolites on central dopaminergic and serotonergic systems.
The Journal of pharmacology and experimental therapeutics 1989;251(3):901-8.
1989: M Johnson; Glen R Hanson; James W Gibb
Characterization of acute N-ethyl-3,4-methylenedioxyamphetamine (MDE) action on the central serotonergic system.
Biochemical pharmacology 1989;38(23):4333-8.
1989: K M Merchant; L G Bush; James W Gibb; Glen R Hanson
Dopamine D2 receptors exert tonic regulation over discrete neurotensin systems of the rat brain.
Brain research 1989;500(1-2):21-9.
1989: D M Stone; Glen R Hanson; James W Gibb
In vitro reactivation of rat cortical tryptophan hydroxylase following in vivo inactivation by methylenedioxymethamphetamine.
Journal of neurochemistry 1989;53(2):572-81.
1989: M Johnson; Glen R Hanson; James W Gibb
Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog.
European journal of pharmacology 1989;165(2-3):315-8.
1989: D M Stone; M Johnson; Glen R Hanson; James W Gibb
Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sites.
European journal of pharmacology 1989;172(1):93-7.
1989: M Johnson; D M Stone; L G Bush; Glen R Hanson; James W Gibb
Glucocorticoids and 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity.
European journal of pharmacology 1989;161(2-3):181-8.
1989: K M Merchant; James W Gibb; Glen R Hanson
Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens.
European journal of pharmacology 1989;160(3):409-12.
1989: Glen R Hanson; P Smiley; M Johnson; A Letter; L Bush; James W Gibb
Response by the neurotensin systems of the basal ganglia to cocaine treatment.
European journal of pharmacology 1989;160(1):23-30.
1989: James W Gibb; M Johnson; Glen R Hanson
MK-801 attenuates the methamphetamine induced decreased in tryptophan hydroxylase activity.
NIDA research monograph 1989;95():511.
1989: James W Gibb; D M Stone; M Johnson; Glen R Hanson
Role of dopamine in the neurotoxicity induced by amphetamines and related designer drugs.
NIDA research monograph 1989;94():161-78.
1989: Glen R Hanson; L P Midgley; L G Bush; M Johnson; James W Gibb
Comparison of responses by neuropeptide systems in rat to the psychotropic drugs, methamphetamine, cocaine and PCP.
NIDA research monograph 1989;95():348.
1989: Glen R Hanson; P Sonsalla; A Letter; K M Merchant; M Johnson; L Bush; James W Gibb
Effects of amphetamine analogs on central nervous system neuropeptide systems.
NIDA research monograph 1989;94():259-69.
1988: M Johnson; Glen R Hanson; James W Gibb
Effects of dopaminergic and serotonergic receptor blockade on neurochemical changes induced by acute administration of methamphetamine and 3,4-methylenedioxymethamphetamine.
Neuropharmacology 1988;27(11):1089-96.
1988: Glen R Hanson; K M Merchant; A A Letter; L Bush; James W Gibb
Characterization of methamphetamine effects on the striatal-nigral dynorphin system.
European journal of pharmacology 1988;155(1-2):11-8.
1988: D M Stone; M Johnson; Glen R Hanson; James W Gibb
Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine.
The Journal of pharmacology and experimental therapeutics 1988;247(1):79-87.
1988: L A Matsuda; CJ Schmidt; James W Gibb; Glen R Hanson
Effects of methamphetamine on central monoaminergic systems in normal and ascorbic acid-deficient guinea pigs.
Biochemical pharmacology 1988;37(18):3477-84.
1988: K M Merchant; A A Letter; James W Gibb; Glen R Hanson
Changes in the limbic neurotensin systems induced by dopaminergic drugs.
European journal of pharmacology 1988;153(1):1-9.
1988: M Johnson; A A Letter; K Merchant; Glen R Hanson; James W Gibb
Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat.
The Journal of pharmacology and experimental therapeutics 1988;244(3):977-82.
1988: G Hanson; L Matsuda; James W Gibb
Neurochemical basis for cocaine and methamphetamine interactions.
NIDA research monograph 1988;81():94-100.
1987: D M Stone; K M Merchant; Glen R Hanson; James W Gibb
Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat.
Neuropharmacology 1987;26(12):1677-83.
1987: Glen R Hanson; K M Merchant; A A Letter; L Bush; James W Gibb
Methamphetamine-induced changes in the striatal-nigral dynorphin system: role of D-1 and D-2 receptors.
European journal of pharmacology 1987;144(2):245-6.
1987: M Johnson; Glen R Hanson; James W Gibb
Effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE) on central serotonergic and dopaminergic systems of the rat.
Biochemical pharmacology 1987;36(23):4085-93.
1987: R T McCabe; James W Gibb; J K Wamsley; Glen R Hanson
Autoradiographic analysis of muscarinic cholinergic and serotonergic receptor alterations following methamphetamine treatment.
Brain research bulletin 1987;19(5):551-7.
1987: D M Stone; Glen R Hanson; James W Gibb
Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats.
Neuropharmacology 1987;26(11):1657-61.
1987: R T McCabe; Glen R Hanson; Ted M Dawson; J K Wamsley; James W Gibb
Methamphetamine-induced reduction in D1 and D2 dopamine receptors as evidenced by autoradiography: comparison with tyrosine hydroxylase activity.
Neuroscience 1987;23(1):253-61.
1987: A A Letter; L A Matsuda; K M Merchant; James W Gibb; Glen R Hanson
Characterization of dopaminergic influence on striatal-nigral neurotensin systems.
Brain research 1987;422(1):200-3.
1987: K M Merchant; A A Letter; M Johnson; D M Stone; James W Gibb; Glen R Hanson
Effects of amphetamine analogs on neurotensin concentrations in rat brain.
European journal of pharmacology 1987;138(1):151-4.
1987: A A Letter; K Merchant; James W Gibb; Glen R Hanson
Effect of methamphetamine on neurotensin concentrations in rat brain regions.
The Journal of pharmacology and experimental therapeutics 1987;241(2):443-7.
1987: James W Gibb; D M Stone; D C Stahl; Glen R Hanson
The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain.
NIDA research monograph 1987;76():316-21.
1987: L A Matsuda; CJ Schmidt; James W Gibb; Glen R Hanson
Ascorbic acid-deficient condition alters central effects of methamphetamine.
Brain research 1987;400(1):176-80.
1986: Glen R Hanson; A A Letter; K Merchant; James W Gibb
Comparison of responses by striatonigral substance P and neurokinin A systems to methamphetamine treatment.
Peptides 1986;7(6):983-7.
1986: D M Stone; D C Stahl; Glen R Hanson; James W Gibb
The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain.
European journal of pharmacology 1986;128(1-2):41-8.
1986: L A Matsuda; CJ Schmidt; Glen R Hanson; James W Gibb
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase and tryptophan hydroxylase in rat.
Neuropharmacology 1986;25(3):249-55.
1984: CJ Schmidt; L A Matsuda; James W Gibb
In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine.
European journal of pharmacology 1984;103(3-4):255-60.